Analyst Upgrades

• Piper Jaffray upgraded Edwards Lifesciences (EW) to overweight from neutral and raised its target price for shares to $77 from $53 after The New England Journal of Medicine reported the company's PARTNER Trial met primary endpoints.
• UBS upgraded Endo Pharmaceuticals (ENDP) to buy from neutral and raised its price target to $36 from $25. UBS is positive on Endo's creative strategic deals and believes the switch to Opana TRF from Opana ER will be easy. Additionally, the analyst believes pipeline expectations are very low.
• BMO Capital upgraded Nvidia (NVDA) to outperform from market perform based on expectations that share loss in the core GPU business will stop, Tegra momentum and valuation. The firm raised its price target to $16 from $9.
• FirstEnergy (FE) and Allegheny Energy (AYE) were upgraded to outperform from neutral at Credit Suisse.
• Mylan (MYL) was upgraded to conviction buy from buy at Goldman. Warner
• Chilcott (WCRX) was upgraded to overweight from equal weight at Morgan Stanley.

Continue reading Analyst Calls: CALM, CWT, DD, DYN, ENDP, EW, MO, MOS, NVDA, OXPS, PPL ...

Analyst Calls: CALM, CWT, DD, DYN, ENDP, EW, MO, MOS, NVDA, OXPS, PPL ... originally appeared on BloggingStocks on Thu, 23 Sep 2010 11:50:00 EST. Please see our terms for use of feeds.

Tuesday morning, drugmaker Mylan (MYL) announced that the Food and Drug Administration (FDA) granted regulatory approval for a generic version of Arimidex, which is produced by AstraZeneca (AZN).

Reportedly, the FDA approved 1-milligram tablets of anastrozole, which is the active ingredient in AstraZeneca's Arimidex. Anastrozole is used to treat some breast cancer in postmenopausal women. This news follows Tueday's approval of a generic version of Arimidex that is produced by Teva Pharmaceutical (TEVA).

Continue reading FDA Approves Mylan's Generic Breast Cancer Drug

FDA Approves Mylan's Generic Breast Cancer Drug originally appeared on BloggingStocks on Tue, 29 Jun 2010 11:20:00 EST. Please see our terms for use of feeds.

Continue reading GlaxoSmithKline Hurt by Generic Valtrex Approval

GlaxoSmithKline Hurt by Generic Valtrex Approval originally appeared on BloggingStocks on Wed, 26 May 2010 12:20:00 EST. Please see our terms for use of feeds.

Analyst Upgrades

• Deutsche Bank upgraded United Parcel Service (UPS) to buy from hold on expectations the company will benefit from improving international package volumes and restructuring initiatives. The firm raised its target on shares to $70 from $67.
• JPMorgan upgraded SVB Financial (SIVB) to overweight from neutral on valuation following the recent pullback in shares. The firm has a $54 price target on the stock.
• Baird upgraded ArvinMeritor (ARM) to outperform from neutral and raised its target to $15 from $12 following the Q2 report. The firm said ArvinMeritor has transformed its business model and is well-positioned for growth.
• UBS (UBS) was upgraded to overweight from neutral at JPMorgan.
• Occidental Petroleum (OXY) was upgraded to conviction buy from buy at Goldman.
• Vail Resorts (MTN) was upgraded to outperform from market perform at Wells Fargo.

Continue reading Analyst Upgrades, Downgrades and Initiations: ARM, KFT, LOW, OXY, UBS, UPS, VRSN ...

Analyst Upgrades, Downgrades and Initiations: ARM, KFT, LOW, OXY, UBS, UPS, VRSN ... originally appeared on BloggingStocks on Wed, 03 Feb 2010 11:00:00 EST. Please see our terms for use of feeds.

Analyst Upgrades

• Stephens upgraded Martin Marietta (MLM) to overweight from equal weight on valuation and expectations that infrastructure and highway spending will increase. The firm raised its target on shares to $105 from $95.
• Janney Montgomery upgraded Shutterfly (SFLY) to buy from neutral to reflect valuation and a reduced pricing overhang after Kodak (EK) raised its 4x6 prices. The firm raised its target on shares to $21 from $18.
• Thomas Weisel upgraded Entropic Communications (ENTR) to overweight from market weight. The firm thinks the company is well-positioned for revenue growth in 2010, partly due to MoCA deployments from new customers and design wins for its silicon tuner product. The firm set a $5 target.
• T. Rowe Price (TROW) was upgraded to buy from hold at Jefferies.
• Dick's Sporting Goods (DKS) was upgraded to buy from neutral at BofA/Merrill.
• Massey Energy (MEE) was upgraded to overweight from neutral at JPMorgan.

Continue reading Analyst upgrades, downgrades and initiations: AOL, CKR, DKS, GEF, MLM, TROW ...

Analyst upgrades, downgrades and initiations: AOL, CKR, DKS, GEF, MLM, TROW ... originally appeared on BloggingStocks on Thu, 10 Dec 2009 11:40:00 EST. Please see our terms for use of feeds.

Here are some highlights from last week's earnings coverage from BloggingStocks:

• Aetna Inc. (NYSE: AET) reported better-than-expected Q3 earnings and revenue, sending shares higher.
• Allergan Inc. (NYSE: AGN) reported better-than-expected Q3 numbers, sending shares higher.
• Bare Escentuals Inc. (NASDAQ: BARE) Q3 profit easily topped analysts' estimates, and shares surged.
• Cabot Oil & Gas Corp. (NYSE: COG) received an upgrade following the release of its Q3 numbers.
• Estee Lauder Companies Inc. (NYSE: EL) reported strong Q1 results, sending shares higher.
• E*Trade Financial Corp. (NASDAQ: ETFC) reported a smaller-than-expected net loss for Q3.
• Goodyear Tire & Rubber Co. (NYSE: GT) Q3 earnings topped estimates and revenue was up sequentially.

Continue reading Earnings highlights: Aetna, Allergan, E*Trade, Goodyear, RadioShack, SAP, Visa ...

Earnings highlights: Aetna, Allergan, E*Trade, Goodyear, RadioShack, SAP, Visa ... originally appeared on BloggingStocks on Sat, 31 Oct 2009 16:10:00 EST. Please see our terms for use of feeds.

One would expect generic U.S. drugmaker Mylan (NYSE: MYL) to benefit from all this talk about increased generic competitions, but revenue only increased 5.2 percent to $1.26 billion on an operational basis, beating analyst revenue estimates of $1.23 billion. Still, revenue in North America, where most pharmas have been hurting, rose 9.2 percent to $502.5 million, helped by new product launches and increased volume.

On an adjusted basis, Mylan posted better-than-expected third-quarter results on Thursday, reporting an earnings per share of 32 cents -- 5 cents higher than the average estimate of analysts polled by Thomson Reuters I/B/E/S. It seems that just like branded pharmas, Mylan benefited from cost cuts. Still, the world's No. 3 generic drugmaker raised its full-year outlook and said it believes it can continue its current momentum into 2010.

Continue reading Pharma earnings recap: Mylan, Allergan, Novo-Nordisk

Pharma earnings recap: Mylan, Allergan, Novo-Nordisk originally appeared on BloggingStocks on Fri, 30 Oct 2009 14:00:00 EST. Please see our terms for use of feeds.

Continue reading Closing Bell: Investors gear down earnings expectations (AIG, HNSN, MRVL, MYL, UNH)

Closing Bell: Investors gear down earnings expectations (AIG, HNSN, MRVL, MYL, UNH) originally appeared on BloggingStocks on Tue, 07 Jul 2009 16:00:00 EST. Please see our terms for use of feeds.

Continue reading Closing Bell: When 2009 highs are under-covered (BAC, ETFC, MYL, PFE, QCOM, STAA)

Closing Bell: When 2009 highs are under-covered (BAC, ETFC, MYL, PFE, QCOM, STAA) originally appeared on BloggingStocks on Thu, 11 Jun 2009 16:10:00 EST. Please see our terms for use of feeds.

Analyst upgrades:

• Goldman upgraded SanDisk (NASDAQ: SNDK) to Buy from Neutral and raised their target to $22 from $16 citing the renegotiated royalty agreement with Samsung.
• Goldman also upgraded Starwood Hotels (NYSE: HOT) to Buy from Sell and raised their target to $27 from $11 citing strong operating leverage as RevPAR recovers.
• KeyBanc upgraded Werner Enterprises (NASDAQ: WERN) to Hold from Underweight citing a recent improvement in freight demand.
• J.C. Penney (NYSE: JCP) was upgraded to buy from Underperform at Banc of America/Merrill.
• Savvis (NASDAQ: SVVS) was raised to Outperform from Perform at Oppenheimer.
• Sanofi-Aventis (NYSE: SNY) was upgraded at Citigroup to Buy from Hold.

Continue reading Analyst upgrades, downgrades and initiations: SNDK, HOT, CAT, HOG, ANF, ERTS ...

Analyst upgrades, downgrades and initiations: SNDK, HOT, CAT, HOG, ANF, ERTS ... originally appeared on BloggingStocks on Thu, 28 May 2009 11:20:00 EST. Please see our terms for use of feeds.

"Few industries seem as well positioned for future growth as the generic drug industry," says small-cap growth stock specialist Tom Bishop.

In his BI Research newsletter, he explains, "With demographic pointing to an increasingly aging population, and healthcare costs spiraling out of control, low cost generic drugs are clearly part of the solution." Here's a look at generic drug maker Mylan (NYSE: MYL).

"High on the agenda of the Obama administration is to bring health care coverage to some 40 million Americans who are currently not covered.

Continue reading Generic gains from Mylan (MYL)

Generic gains from Mylan (MYL) originally appeared on BloggingStocks on Mon, 18 May 2009 12:30:00 EST. Please see our terms for use of feeds.

• Bernstein upgraded Merck (NYSE: MRK) to Outperform from Market Perform and raised its target to $30 from $27 citing valuation and its decision to buy Schering-Plough, at what appears to be a reasonable price.
  
• RBC Capital upgraded Palm (NASDAQ: PALM) to Outperform from Sector Perform and raised its target to $12 from $5 as it believes webOS has increased its chances for Smartphone leadership and will increase its attractiveness as an acquisition target.
  
• RW Baird upgraded Alcatel-Lucent (NYSE: ALU) to Outperform from Neutral on valuation as it believes balance sheet risks are overly discounted in the stock, creating a buying opportunity. The firm has a $3 target on shares.
• Express Scripts (NASDAQ: ESRX) was raised to Buy from Hold at Argus.
  
• France Telecom (NYSE: FTE) was upgraded at Morgan Stanley to Equal Weight from Underweight.
  
• Foster Wheeler (NASDAQ: FWLT) was upgraded to Conviction Buy from Neutral at Goldman.

Continue reading Analyst upgrades, downgrades and initiations: MRK, PALM, DNA, WMT, TEVA ...

Analyst upgrades, downgrades and initiations: MRK, PALM, DNA, WMT, TEVA ... originally appeared on BloggingStocks on Fri, 13 Mar 2009 11:00:00 EST. Please see our terms for use of feeds.

• Banc of America/Merrill upgraded DPL Inc (NYSE: DPL) to Neutral from Underperform following the settlement agreement with staff of the Public Utilities Commission of Ohio on Electric Security Plan.
  
• Friedman Billings upgraded SeaBright Insurance (NYSE: SBX) to Outperform from Market Perform on valuation as they believe shares are oversold at current levels. Despite upgrading, the firm lowered its target price to $14 from $16.
  
• JP Morgan upgraded AT&T (T) to Overweight from Neutral as it believes upside earnings revisions are likely in 2009 due to the company's conservative wireline margin outlook. The firm finds the stock's valuation attractive at current levels and raised their target on shares to $28 from $24.
• Chubb (NYSE: CB) was upgraded to buy from Neutral at UBS.
  
• Cascal B.V. (NYSE: HOO) was raised to Outperform from Neutral at Credit Suisse.
  
• Healthcare Realty Trust (NYSE: HR) was upgraded at Keefe Bruyette to Outperform from Market Perform.

Continue reading Analyst upgrades, downgrades and initiations: T, FSLR, CEPH, CB ...

Analyst upgrades, downgrades and initiations: T, FSLR, CEPH, CB ... originally appeared on BloggingStocks on Wed, 25 Feb 2009 10:45:00 EST. Please see our terms for use of feeds.

• Citigroup upgraded Blue Nile (NASDAQ: NILE) shares to Buy from Hold on valuation following the recent sell-off as they believe weakening fundamentals have been factored into estimates and that Blue Nile should benefit from the recent softening of diamond prices. The firm raised its target price to $30 from $20.
  
• Baird upgraded AmSurg (NASDAQ: AMSG) to Outperform from Neutral based on valuation, potential upside from in-line results, good visibility, and FCF yield.
  
• Oppenheimer upgraded DryShips (NASDAQ: DRYS) to Perform from Underperform on valuation following the recent weakness and believes the company is at least halfway through its $500M equity offering.
• UAL Corp (NASDAQ: UAUA) was raised to Buy from Neutral at Banc of America/Merrill.
  
• Mylan (NASDAQ: MYL) was upgraded to Overweight from Equal Weight at Barclays.
  
• Exxon Mobil (NYSE: XOM) was lifted at Deutsche Bank to Buy from Hold.

Continue reading Analyst upgrades, downgrades and initiations: NILE, XOM, MT, NFLX ...

Analyst upgrades, downgrades and initiations: NILE, XOM, MT, NFLX ... originally appeared on BloggingStocks on Mon, 23 Feb 2009 12:00:00 EST. Please see our terms for use of feeds.

Analyst upgrades:

• Goldman added McDonald's (NYSE:MCD) to its Conviction Buy List as they believe the company will beat their earnings expectations over the next couple quarters. Note that Burger King (NYSE:BKC) was removed from the list.
  
• Baird upgraded Woodward Govenor (NASDAQ:WGOV) to Outperform from Neutral citing increased confident in its outlook following the better-than-expected Q1 report.
  
• Citigroup upgraded Harley-Davidson (NYSE:HOG) to Hold from Sell and removed shares from their Top Picks Live List as a Sell as they believe current expectations are very low following the recent weakness. Citigroup lowered their target price to $13 from $18.
• Ford (NYSE:F) and Lear (NYSE:LEA) were upgraded to Hold from Sell at Deutsche Bank.
  
• KT Corp (NYSE:KTC) was raised to Overweight from Neutral at HSBC.
  
• Ryanair (NASDAQ:RYAAY) was upgraded to Hold from Sell at Collins Stewart and to Buy from Neutral at UBS.

• Goldman removed Burger King (NYSE:BKC) from its Conviction Buy List citing recent share strength. Note that McDonald's (NYSE:MCD) was added to the list.
  
• Keefe Bruyette downgraded shares of Och-Ziff Capital (NYSE:OZM) to Market Perform from Outperform to reflect the company's near-term headwinds. The firm lowered their target to $5 from $6.50.
  
• Morgan Stanley downgraded Freeport-McMoRan (NYSE:FCX), Alcoa (NYSE:AA), and Century Aluminum (NASDAQ:CENX) to Equal Weight from Overweight as they believe industrial metals will be depressed through next year.
• Air France (Other OTC:AFLYY) was downgraded to Sell from Neutral at UBS.
  
• Wal-Mart (NYSE:WMT) was lowered to Neutral from Outperform at Credit Suisse.
  
• Radware (NASDAQ:RDWR) was cut at Argus to Hold from Buy.

• Merriman initiated Suntech (NYSE:STP) with a Sell rating. The firm is concerned by the company's debt load and narrowing maturity and thinks further cost reduction in China could be a challenge. The firm believes a fair price target range is $3.50-$4.50 per share.
  
• JMP Securities views Google (NASDAQ:GOOG) as a long-term "must buy" given its dominant market position, strong balance sheet, and low valuation. Shares were initiated with an Outperform rating and $400 target.
  
• Auriga started Micron (NYSE:MU) with a Buy rating and $5 target. The firm expects DRAM oversupply to ease in the second half of 2009 and believes Micron will not burn significant cash this year.
• Qualcomm (NASDAQ:QCOM) was initiated at Morgan Stanley with an Equal Weight rating and $41 target.
  
• Core Laboratories (NYSE:CLB) was initiated with a Buy rating and $80 target at Wunderlich.
  
• Mylan (NASDAQ:MYL) was started with a Buy rating and $16 target at Citigroup.

Analyst upgrades, downgrades and initiations: MCD, BKC, F, GOOG, OZM, WMT originally appeared on BloggingStocks on Wed, 21 Jan 2009 11:57:00 EST. Please see our terms for use of feeds.

Analyst upgrades:

• UBS upgraded Kansas City Southern (NYSE:KSU) to Buy from Neutral and lowered its target to $26 from $35 citing valuation.
  
• Gabelli upgraded Media General (NYSE:MEG) to Hold from Sell because the firm thinks that Harbinger Capital has sold most of its shares in the company. As a result, the firm thinks the stock will be under less selling pressure.
  
• Eagle Bulk Shipping (NASDAQ:EGLE) was upgraded to Neutral from Underperform at Merrill Lynch.
• Centene (NYSE:CNC) was raised to Buy from Neutral at Goldman.
  
• Ralcorp (NYSE:RAH) was upgraded at Credit Suisse to Outperform from Neutral.
  
• Interpublic Group (NYSE:IPG) was upgraded to Equal Weight from Underweight at Morgan Stanley.

• Keefe Bruyette downgraded Healthcare Realty(NYSE:HR) to Market Perform from Outperform on concerns the company's development activity could be dilutive to near-term earnings.
  
• Citigroup downgraded Satyam (NYSE:SAY) to Sell from Buy as they believe the company's acquisition plans, and subsequent cancellation of the deals, will lessen investor confidence in the name.
  
• Oppenheimer downgraded Apple (NASDAQ:AAPL) to Perform from Outperform citing Steve Jobs cancellation of his annual key note speech at Macworld on January 6. The analyst said the unexpected announcement underscores Apple's long-term dependence on Job's health and its lack of succession plan.
• Baird downgraded Carlisle NYSE:CSL)to Neutral from Outperform.
  
• Gibraltar Industries (NASDAQ:ROCK) was downgraded at Piper Jaffray to Sell from Buy.
  
• NetApp (NASDAQ:NTAP) was cut to Accumulate from Buy at ThinkPanmure.

• Citigroup believes the acquisition of Barr enhances Teva's (NASDAQ:TEVA) growth. The firm started shares with a Buy rating and $52 target.
  
• Suntrust initiated American Express (NYSE:AXP) with a Reduce citing slowing growth and greater-than-industry deterioration in credit quality.
  
• Roth Capital initiated The Buckle (NYSE:BKE) with a Hold rating and $17 target citing the deteriorating macro environment.
• Amazon.com (NASDAQ:AMZN) and Allegheny Tech (NYSE:ATI) were assumed with Neutral ratings and targets of $52 and $26, respectively, at UBS.
  
• Digital Realty (NYSE:DLR) was initiated at Piper Jaffray with a Buy rating.
  
• Mylan (NYSE:MYL) was started with an Overweight rating and $15 target at JP Morgan.

Analyst upgrades, downgrades and initiations: AAPL, AXP, AMZN, KSU, IPG originally appeared on BloggingStocks on Wed, 17 Dec 2008 12:38:00 EST. Please see our terms for use of feeds.

Analyst upgrades:

• JMP Securities upgraded Vertex Pharma (NASDAQ: VRTX) to Outperform from Market Perform following better-than-expected interim data for telaprevir.
  
• Lazard Capital upgraded shares of Biogen Idec (NASDAQ: BIIB) to Buy from Hold on valuation after their physician survey indicated solid sales growth in the company's MS franchise.
  
• Calyon upgraded Data Domain (NASDAQ: DDUP) to Add from Neutral based on positive channel checks and valuation.
• Goldman added Buckeye GP (NYSE: BGH) to the Conviction Buy List.
  
• Alcatel-Lucent (NYSE: ALU) was upgraded to Hold from Sell and Ericsson (NASDAQ: ERIC) was raised to Hold from Reduce at WestLB.
  
• Keefe Bruyette upgraded Cowen Group (NASDAQ: COWN) to OUtperform from Market Perform.

• Deutsche Bank downgraded shares of Lloyds TSB Group (NYSE: LYG) to Sell from Hold as they believe loan loss risk will outweigh synergies from the acquisition of HBOS (HBOOY).
  
• Citigroup downgraded shares of National Financial Partners (NYSE: NFP) to Hold from Buy and removed the stock from the Top Picks Live List after the company announced July and August revenues and said pressure continues. The firm lowered their target to $20 from $28.

Continue reading Analyst calls: BIIB, ALU, LYG, MAR, HOT, JCP, MYL, CBS ...

Analyst calls: BIIB, ALU, LYG, MAR, HOT, JCP, MYL, CBS ... originally appeared on BloggingStocks on Thu, 25 Sep 2008 11:40:00 EST. Please see our terms for use of feeds.

With a turn of the calendar page, we drift into the middle portion of the current quarter, but the earnings season rolls on. Among the many companies scheduled to report quarterly results this coming week are Time Warner Inc. (NYSE: TWX), Cisco Systems Inc. (NASDAQ: CSCO), News Corp. (NYSE: NWS), and Whole Foods Market International (NASDAQ: WFMI). Let's take a look at which companies Wall Street analysts are expecting to be among the top earnings gainers and decliners this week.

Analysts surveyed by Thomson Financial expect the following to report strong earnings growth when compared to the same period of the previous year.

• DRS Technologies Inc. (NYSE: DRS): $0.85 EPS (+95.3%) on revenue of $823.8 million (+12.0%)
• Integrys Energy Group Inc. (NYSE: TEG): $0.40 EPS (+70.0%) on revenue of $2.6 billion (+9.7%)
• Cimarex Energy Co. (NYSE: XEC): $2.53 EPS (+64.4%) on revenue of $599.9 million (+75.4%)
• Forest Oil Corp. (NYSE: FST): $1.51 EPS (+55.6%) on revenue of $456.1 million (+79.1%)
• Devon Energy Corp. (NYSE: DVN): $3.28 EPS (+48.5%) on revenue of $4.1 billion (+38.5%)
• CMS Energy Corp. (NYSE: CMS): $0.13 EPS (+46.2%) on revenue of $1.4 billion (+6.7%)
• Transocean Inc. (NYSE: RIG): $3.23 EPS (+43.0%) on revenue of $3.1 billion (+112.9%)
• Sara Lee Corp. (NYSE: SLE): $0.26 EPS (+38.5%) on revenue of $3.5 billion (+8.9%)
• Williams Companies Inc. (NYSE: WMB): $0.69 EPS (+37.7%) on revenue of $3.4 billion (+20.0%)
• Harris Corp. (NYSE: HRS): $0.99 EPS (+28.3%) on revenue of $1.4 billion (+18.0%)

Continue reading The week in preview: Expectations remain high for energy and oil

The week in preview: Expectations remain high for energy and oil originally appeared on BloggingStocks on Sun, 03 Aug 2008 12:30:00 EST. Please see our terms for use of feeds.

MOST NOTEWORTHY:

• Deutsche Bank downgraded shares of Stanley Works (NYSE: SWK) to Hold from Buy as they see risk to Q2 and FY08 earnings due to a slowdown in the European industrial and consumer categories. The firm lowered their target to $52 from $62.
  
• Wachovia cut the Generic Drug sector to Market Weight from Overweight Wachovia sees near-term challenges for Teva Pharmaceutical (NASDAQ: TEVA), Mylan (NYSE: MYL) and Watson Pharmaceuticals (NYSE: WPI). The firm thinks Teva will become a very strong company over the long-term, following its takeover of Barr (NYSE: BRL). However, the firm adds that Teva will need to integrate the acquisition nearly perfectly, and Mylan may feel compelled to make another acquisition, even as it is still integrating Merck Generics, while Watson's growth prospects are still uncertain.
  
• Oppenheimer downgraded Fiserv (NASDAQ: FISV) and Fidelity National (NYSE: FIS) to Perform from Outperform based on multiple pressure from the challenging banking environment and growth headwinds.

• Satyam (NYSE: SAY) was downgraded to Underperform from Outperform at Credit Suisse and Equal Weight from Overweight at Morgan Stanley.
  
• UBS downgraded Textron (NYSE: TXT) to Neutral from Buy.
  
• Constellation Energy (NYSE: CEG) was downgraded at Jefferies to Underperform from Hold.

Analyst downgrades: SWK, Generic drug sector, FISV and FIS originally appeared on BloggingStocks on Mon, 21 Jul 2008 11:11:00 EST. Please see our terms for use of feeds.

MOST NOTEWORTHY:

• Kaufman Bros. believes Drugstore.com (NASDAQ: DSCM) is well-positioned for long-term growth and significant margin expansion, led by share gains in the OTC and prestige beauty verticals. The firm started shares with a Buy rating and $3.25 target.
  
• Merriman initiated Sycamore (NASDAQ: SCMR) with a Neutral rating and prefers to be on the sidelines given the company's concentrated customer base and lack of clarity on strategic priorities and ongoing business operations.
  
• SunTrust Robinson expects the Aflac's (NYSE: AFL) cancer insurance policies in Japan to benefit from concerns about the national health system. Shares were assumed with a Buy rating and $79 target.

• Caris initiated Mylan (NYSE: MYL) with a Buy rating and $18 target.
  
• NetSuite (NYSE: N) was assumed with a Hold rating and $22 target at Deutsche Bank.
  
• Stanford initiated Time Warner (NYSE: TWX) with a Buy rating and $20 target.

Analyst initiations: DSCM, SCMR and AFL originally appeared on BloggingStocks on Fri, 13 Jun 2008 11:14:00 EST. Please see our terms for use of feeds.